QUALITY OF ANTI-COAGULATION, PREDICTORS, AND CONSEQUENCES OF DERANGED INR OF PATIENTS ON WARFARIN THERAPY

AKANKSHA MATHUR; ACHAL SHARMA

doi:10.22159/ajpcr.2024v17i12.52969

Authors

AKANKSHA MATHUR Department of Pharmacology, K.D. Medical College, Hospital and Research Centre, Mathura, Uttar Pradesh, India https://orcid.org/0000-0002-8155-4923
ACHAL SHARMA Department of Cardiology, K.D. Medical College, Hospital and Research Centre, Mathura, Uttar Pradesh, India.

DOI:

https://doi.org/10.22159/ajpcr.2024v17i12.52969

Keywords:

International Normalized Ratio, Time in therapeutic range (TTR), Adverse drug reaction, Adverse drug events, Anticoagulants

Abstract

Objective: Warfarin therapy is considered challenging because of the narrow therapeutic index and various pharmacokinetic and pharmacodynamic interactions. Inability to maintain the international normalized ratio (INR) in therapeutic range results into adverse events. The study aims to characterize the quality of anti-coagulation with warfarin and its outcome in terms of adverse events along with analysis of various predictors for INR control.

Methods: A cross-sectional study was conducted at a tertiary care center involving all adult patients (≥18 years) on warfarin therapy presenting to the cardiology outpatient department for 1 year. Current INR, time in therapeutic range (TTR), and adverse events, if any were documented and managed appropriately. Logistic regression analysis was used to calculate odds ratios and 95% confidence intervals (CI) to model the predictors of deranged INR values.

Results: Of all 425 patients, 164 (38.58%) patients had non-target INR values, 111 (26.11%) were subtherapeutic, and 53 (12.47%) were supratherapeutic. Increased incidence of subtherapeutic range INR was found in women (IRR=1.09; p=0.002) and in patients with valvular atrial fibrillation (IRR=1.24; p<0.001). On the other hand, increased incidence of supratherapeutic INR was found in patients having renal failure (IRR=1.12; p<0.001). Four (2.4%) patients with subtherapeutic INR developed stroke and 3 (1.92%) patients with high INR resulted into bleeding.

Conclusion: The study found low percentage of TTR in patients on warfarin therapy. Predictors for poor anticoagulation control were women, valvular atrial fibrillation, renal failure along with drug interactions, and non-adherence to therapy.

Downloads

Download data is not yet available.

References

Van Walraven C, Jennings A, Oake N, Fergusson D, Forster AJ. Effect of study setting on anticoagulation control: A systematic review and metaregression. Chest. 2006;129(5):1155-66. doi: 10.1378/ chest.129.5.1155, PMID 16685005

Chebrolu P, Patil S, Laux TS, Al-Hammadi N, Jain Y, Gage B. Quality of anticoagulation with warfarin in rural Chhattisgarh, India. Indian J Med Res. 2020;152(3):303-307. doi: 10.4103/ijmr.IJMR_1201_18, PMID 33107491

Van Miert JH, Bos S, Veeger NJ, Meijer K. Clinical usefulness of the SAMe-TT2R2 score: A systematic review and simulation meta-analysis. PLoS One. 2018;13(3):e0194208. doi: 10.1371/journal. pone.0194208, PMID 29534092

Medscape.com. Available from: https://reference.medscape.com/drug-interactionchecker [Last accessed on 2024 Oct 16].

Jeny RE, Sabu JS, Murthy MK, Madappa NU. Oral anticoagulant prescription analysis for utilisation pattern among in-patients at a tertiary care hospital. Int J Pharm Pharm Sci. 2018;10(3):76. doi: 10.22159/ ijpps.2018v10i3.24102

Sonuga BO, Hellenberg DA, Cupido CS, Jaeger C. Profile and anticoagulation outcomes of patients on warfarin therapy in an urban hospital in Cape Town, South Africa. Afr J Prim Health Care Fam Med. 2016;8(1):e1-8. doi: 10.4102/phcfm.v8i1.1032

Takamoto K, Sakamoto JI, Ito S, Kimura T, Manabe E, Shikata T, et al. Low quality of warfarin therapy is associated with female gender but not with polypharmacy in patients with atrial fibrillation. Front Pharmacol. 2021 Apr 26;12:651799. doi: 10.3389/fphar.2021.651799, PMID 33981231

Avarello I, Bianchi S, Toschi V, Zighetti ML, Faioni EM. Time in therapeutic range is lower in women than in men and is not explained by differences in age or comorbidity. Thromb Res. 2021;203:18-21. doi: 10.1016/j.thromres.2021.04.011, PMID 33901765

Zulkifly HH, Pastori D, Lane DA, Lip GY. Anticoagulation control and major adverse clinical events in patients with operated valvular heart disease with and without atrial fibrillation receiving vitamin K antagonists. J Clin Med. 2023;12(3):1141. doi: 10.3390/jcm12031141, PMID 36769789

Pastori D, Lip GY, Poli D, Antonucci E, Rubino L, Menichelli D, et al. Determinants of low‐quality warfarin anticoagulation in patients with mechanical prosthetic heart valves. The nationwide PLECTRUM study. Br J Haematol. 2020;190(4):588-593. doi: 10.1111/bjh.16528, PMID 32080833

Rizk DV, Warnock DG. Warfarin-related nephropathy: Another newly recognized complication of an old drug. Kidney Int. 2011 Jul;80(2):131-3. doi: 10.1038/ki.2011.85, PMID 21720303

Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005;165(10):1095-106. doi: 10.1001/archinte.165.10.1095, PMID 15911722

Teka F, Korsa A, Bayisa HG, Fida HY, Senbeta BS. Adverse clinical outcomes of warfarin therapy and predictors among adult outpatients at public hospitals in Nekemte town, western Ethiopia: A retrospective cross-sectional study. Thromb Update. 2024;15:100170.

Mujtaba M, Khanzada MF, Aman S, Ahmed K, Ahmed N, Haider MU, et al. Predisposing factors leading to warfarin toxicity. J Pharm Res Int. 2022:23-29. doi: 10.9734/jpri/2022/v34i32B36116

Siddiqui S, Deremer CE, Waller JL, Gujral JS. Variability in the calculation of time in therapeutic range for the quality control measurement of warfarin. J Innov Card Rhythm Manag. 2018;9(12):3428-34. doi: 10.19102/icrm.2018.091203, PMID 32494479